Opendata, web and dolomites

PRINT-CHEMO SIGNED

To develop 3D bioPRINTed osteoinductive constructs that deliver CHEMOtherapeutics within large bone defects that are surgically created when removing bone tumours.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PRINT-CHEMO project word cloud

Explore the words cloud of the PRINT-CHEMO project. It provides you a very rough idea of what is the project "PRINT-CHEMO" about.

cells    15    diagnosed    standard    self    45    chemotherapeutics    usa    tumours    dose    exercise    initial    3d    understand    surviving    nanoparticles    heterogeneity    cues       therapy    systemic    bones    aberration    aged    assembled    osteosarcoma    approximately    children    survival    rate    chemo    socioeconomic    outcome    predominantly    relapse    disease    radiation    chemotherapy    bone    printing    treat    molecular    14    194    resection    costly    tibia    localised    body    resistant    mir    first    progress    diagnosis    tumour    regenerate    united    young    61    age    50    18    adolescents    trying    metaphysis    rates    distal    clones    24    evolutionary    last    initiates    time    gene    gold    suppressive    femur    made    diseased    proximal    humerus    loaded    billion    patients    wave    damaged    drug    hypothesis    treatment    relatively    print    caused    adjuvant    tissue    subset    pattern    dendritic   

Project "PRINT-CHEMO" data sheet

The following table provides information about the project.

Coordinator
THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN 

Organization address
address: College Green
city: DUBLIN
postcode: 2
website: www.tcd.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 257˙561 €
 EC max contribution 257˙561 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-GF
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2022-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN IE (DUBLIN) coordinator 257˙561.00
2    THE BRIGHAM AND WOMEN'S HOSPITAL INC US (BOSTON MA) partner 0.00

Map

 Project objective

Osteosarcoma is the most commonly diagnosed bone tumour with most of these cases being in children and adolescents. Each year over 4,000 new cases of osteosarcoma are diagnosed in the United States. Osteosarcoma predominantly initiates in the metaphysis of long bones, such as the distal femur, proximal tibia and proximal humerus. Over 50% of these tumours are relatively resistant to radiation therapy, due to the molecular aberration of the tumour. The current gold standard for treatment is tumour resection and adjuvant chemotherapy, with a 5-year survival rate of 61.6% in patients aged 0-24 years old. Approximately one-third of patients diagnosed with osteosarcoma are expected to have a relapse, with only 15% of these patients surviving the disease a second time. Therefore, due to the young age of initial diagnosis, the management of this disease is a challenging and costly exercise, which has a significant socioeconomic cost, estimated to be €14.7 billion in Europe and $45 billion in the USA in the last 18 years. While significant progress has been made in trying to understand the intra-tumour heterogeneity and the evolutionary pattern of a subset of clones within the tumour, thus far, no major changes in treatment and outcome have been achieved. The hypothesis of PRINT-CHEMO is that localised delivery of self-assembled dendritic nanoparticles used as a first wave of treatment to deliver miR-194, a tumour suppressive gene, to the cells along with the delivery of nanoparticles loaded with chemotherapeutics would lead to higher survival rates and less side effects than systemic delivery of a higher dose of drug. Furthermore, PRINT-CHEMO not only aims to treat the diseased tissue but using 3D printing provide the necessary cues to allow for the body to regenerate the damaged bone caused due to tumour resection.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PRINT-CHEMO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PRINT-CHEMO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

PNAIC (2018)

Positive and Negative Asymmetry in Intergroup Contact: Its Impact on Linguistic Forms of Communication and Physiological Responses

Read More  

MIGPSC (2018)

Shaping the European Migration Policy: the role of the security industry

Read More  

FrogsInSpace (2019)

From ecology to neurobiology: spatial cognition in rainforest frogs

Read More